Evidence map›Paper›PMID 39605810›Full record

ArticleHeliyon2024

Impact of SARS-CoV-2 variants on COVID-19 symptomatology and severity during five waves.

Bruno Belmonte Martinelli Gomes, Natasha Nicos Ferreira, Pedro Manoel Marques Garibaldi, Cassia Fernanda Sales de Lima Dias, Letícia Nakamura Silva, Maria Aparecida Alves Leite Dos Santos Almeida, Glenda Renata de Moraes, Dimas Tadeu Covas, Simone Kashima, Rodrigo Tocantins Calado and 3 more

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Bruno Belmonte Martinelli GomesUniversity of São Paulo, Ribeirão Preto Medical School, Avenida Bandeirantes, 3900, Ribeirão Preto, SP, Brazil.
Natasha Nicos FerreiraClinical Research Center - S, Rua Treze de Maio, 438, Serrana, SP, Brazil.
Pedro Manoel Marques GaribaldiClinical Research Center - S, Rua Treze de Maio, 438, Serrana, SP, Brazil.
Cassia Fernanda Sales de Lima DiasClinical Research Center - S, Rua Treze de Maio, 438, Serrana, SP, Brazil.
Letícia Nakamura SilvaClinical Research Center - S, Rua Treze de Maio, 438, Serrana, SP, Brazil.
Maria Aparecida Alves Leite Dos Santos AlmeidaButantan Institute, São Paulo, SP, Brazil.
Glenda Renata de MoraesHealth Department, Rua Tancredo de Almeida Neves, 95, Serrana, SP, Brazil.
Dimas Tadeu CovasUniversity of São Paulo, Ribeirão Preto Medical School, Avenida Bandeirantes, 3900, Ribeirão Preto, SP, Brazil.
Simone KashimaCenter for Cell-based Therapy, Blood Center of Ribeirão Preto, Rua Tenente Catão Roxo, 2501, Ribeirão Preto, SP, Brazil.
Rodrigo Tocantins CaladoUniversity of São Paulo, Ribeirão Preto Medical School, Avenida Bandeirantes, 3900, Ribeirão Preto, SP, Brazil.
Benedito Antônio Lopes FonsecaUniversity of São Paulo, Ribeirão Preto Medical School, Avenida Bandeirantes, 3900, Ribeirão Preto, SP, Brazil.
Gustavo Jardim VolpeClinical Research Center - S, Rua Treze de Maio, 438, Serrana, SP, Brazil.
Marcos de Carvalho BorgesUniversity of São Paulo, Ribeirão Preto Medical School, Avenida Bandeirantes, 3900, Ribeirão Preto, SP, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: SARS-CoV-2 variants have distinct features of transmissibility, infectivity, and aggressiveness that may cause different clinical manifestations. A better understanding of the disease presentation and progression could help to outline more precise preventive and treatment frameworks. This study describes the differences in COVID-19 presentation and outcomes across five variant waves. Methods: This prospective cohort was conducted in Serrana, São Paulo State, Brazil. Clinical and demographic data was obtained from June 2020 to December 2022 as part of an enhanced health surveillance system for COVID-19, based on increasing access to diagnostic testing for SARS-CoV-2 and patient follow-up. Individuals were assessed for COVID-19 symptoms and comorbidities. Mild cases were followed up for at least 14 days, and severe cases until discharge or death. Samples were genetically sequenced, and variant waves were determined based on global SARS-CoV-2 variant predominance (>90 % sequenced samples), being as follows: Ancestral, Delta, Gamma, Omicron BA.1, and Omicron BA.2 waves. The relationship between clinical data and disease outcomes was analyzed in each variant wave. Results: Patients infected during the Delta wave were the youngest (36.1 ± 18.2 years, p < 0.001). The proportion of female patients was higher across all waves. Positivity rate, disease severity, and COVID-19-related deaths varied among them. Ageusia and anosmia were related to SARS-CoV-2 positivity during the Ancestral, Gamma, and Delta waves but not in Omicron BA.1 and Omicron BA.2 waves. Diarrhea presented a lower chance of positivity only in Omicron BA.1 and Omicron BA.2. Dyspnea was the most consistent risk factor for severity across all waves. Conclusions: Although patients with COVID-19 from different SARS-CoV-2 variants shared some clinical-epidemiological characteristics, each variant presented distinguishable features related to positivity and severity. This could help to understand the dynamics of COVID-19 variants and update recommendations for clinical practice.

Indexed as

COVID-19SARS-CoV-2SeveritySymptoms

Identifiers

PMID39605810
PMCPMC11600076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.